Orchid Chem and Stride Arcolabs remain star stocks to watch out for, their grasp of global markets and ability to sell in the generics/branded generics/APIs space beign on par or better than Biocon ( Biocon having branched out into generics and APIs a long time back and no longer a "Bio tech play") 

Orchid also tracks a $1 bln run rate in sales but profitability has been hit hard this quarter down 50%. We'll update this analysis too.